DOCSLIB.ORG

Regional Differences in Prescribing Patterns of Metamizole in Germany

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regional Differences in Prescribing Patterns of Metamizole in Germany International Journal of Environmental Research and Public Health Article Regional Differences in Prescribing Patterns of Metamizole in Germany Based on Data from 70 Million Persons Falk Hoffmann 1 , Carsten Bantel 2, Frederik Tilmann von Rosen 1 and Kathrin Jobski 1,* 1 Department of Health Services Research, Carl von Ossietzky University Oldenburg, 26129 Oldenburg, Germany; falk.hoff[email protected] (F.H.); [email protected] (F.T.v.R.) 2 University Department of Anesthesiology, Critical Care, Emergency and Pain Medicine, Klinikum Oldenburg, 26133 Oldenburg, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-(0)441-798-2330 Received: 8 May 2020; Accepted: 28 May 2020; Published: 30 May 2020 Abstract: The non-opioid analgesic metamizole (dipyrone) is commonly used in Germany despite its narrow indications and market withdrawal from several countries. In this study we analyzed prescribing patterns of metamizole focusing on regional differences. The source of data was the “Information system for health care data” which includes data from the statutory health insurance funds for about 70 million Germans. We received aggregated data of individuals with at least one metamizole prescription in 2010 as well as the number of prescribed packages by age, sex, state and district along with the number of insured persons in each stratum. We calculated prescription prevalence stratified by age, sex, state and district. Among 68.4 million insured persons (mean age: 43.6 years; 53.0% female) 5.5 million received at least one metamizole prescription (8.1%, overall 12.2 million packages). Prevalence increased with age, and women received metamizole more often than men. In adults (total prevalence: 9.4%), levels varied between 7.0% (Saxony) and 11.1% (Schleswig-Holstein), whereas on a district level use ranged from 4.3% to 14.3%. In 2010, one of 12 individuals received metamizole at least once. Noticeable were the large regional variations which certainly cannot be explained by patient-related factors. Keywords: metamizole; dipyrone; prescribing patterns; prevalence; regional variations; Germany 1. Introduction Metamizole is a non-opioid analgesic. It has been available for nearly a century, and can be placed in the first step on the World Health Organization (WHO) analgesic ladder. It shows good analgesic, antipyretic and spasmolytic efficacy, although studies have been largely confined to the acute setting [1–3]. Compared to nonsteroidal anti-inflammatory drugs (NSAIDs) or opioids, metamizole seems to display a favorable profile of renal and gastrointestinal risks [3,4]. Yet, the safety of metamizole has been the topic of a lengthy and controversial debate due to the possibility of agranulocytosis as a grave and potentially fatal adverse effect [3,5–7]. Although the true incidence of metamizole-induced agranulocytosis is unclear and varies widely between studies [8–12], many countries including the UK, France, Norway, Sweden, the USA, Canada and Australia have decided to withhold or withdraw market authorization, while it is available over-the-counter (OTC) in others [5]. Germany subjected metamizole to prescription-only status in 1987, and actively narrowed its indications [13]. Nonetheless, metamizole remains a widely used medication in Germany, both in inpatient and outpatient settings [14–16]. According to the annual German Drug Prescription Report, prescription volume among outpatients increased fifteen-fold between 1991 and 2018 (Figure1), from 15 to 225 million defined daily doses (DDD) [17–19]. The DDD describes the assumed average maintenance Int. J. Environ. Res. Public Health 2020, 17, 3892; doi:10.3390/ijerph17113892 www.mdpi.com/journal/ijerph Int. J. Environ. Res. Public Health 2020, 17, 3892 2 of 10 doseInt. J. per Environ. day Res. for Public a drug Health used2020 for, 17 ,its 3892 main indication in adults [20]. For metamizole, the DDD is 3 2 ofg. 9 Correspondingly, a total of 675 tons of metamizole were prescribed to members of statutory health funds in Germany in 2018, which would translate to 18.5 tablets of 500 mg for each insured individual (Figuredose per 1). day However, for a drug the usedyearly for prescription its main indication volume by in adultsitself lacks [20]. the For information metamizole, necessary the DDD to is evaluate3 g. Correspondingly, the true number a total of pati ofents 675 tonsprescribed of metamizole metamizole, were the prescribed doses prescribed, to members and of to statutory assess regionalhealth funds differences. in Germany An earlier in 2018, study which using would data from translate one health to 18.5 insurance tablets of 500fund mg pointed for each towards insured a higherindividual prescription (Figure1 ).prevalence However, in the northwestern yearly prescription Germany, volume lower by levels itself lacksin southern the information Germany, necessary and the lowestto evaluate level thein eastern true number Germany. of patients Prevalence prescribed varied metamizole, visible between the doses states prescribed, (Bundesländer), and to assesswith betweenregional 4.9% differences. and 8.3% An earlierreceiving study at least using one data prescription from one health of metamizole insurance fundin 2009 pointed [15]. towardsTo our knowledge,a higher prescription no study has prevalence been performed in northwestern with greate Germany,r geographic lower resolution levels in southern than at the Germany, state level, and althoughthe lowest it can level be in assumed eastern Germany.that marked Prevalence differences varied exist visibleeven within between states. states (Bundesländer), with betweenThe 4.9%aim of and this 8.3% study receiving is to provide at least onean prescriptioninsight into ofthe metamizole number of in metamizole 2009 [15]. To prescriptions our knowledge, in outpatientno study has care, been with performed a particular with focus greater on geographicregional differences resolution on than the atdistrict the state (Landkreis) level, although level. it can be assumed that marked differences exist even within states. Figure 1. Prescriptions of metamizole in Germany from 1991 to 2018 (according to the Annual Drug Figure 1. Prescriptions of metamizole in Germany from 1991 to 2018 (according to the Annual Prescription Reports [17–19]), displayed as defined daily doses (DDD); 1 DDD = 3 g (lower caption) as Drug Prescription Reports [17–19]), displayed as defined daily doses (DDD); 1 DDD = 3 g (lower well as the calculated number of 500 mg tablets per insured person (upper italic caption). caption) as well as the calculated number of 500 mg tablets per insured person (upper italic caption). The aim of this study is to provide an insight into the number of metamizole prescriptions in 2.outpatient Materials care, and withMethods a particular focus on regional differences on the district (Landkreis) level. We obtained data from the “Information System for Health Care Data” located at the German 2. Materials and Methods Institute of Medical Documentation and Information (DIMDI) [21]. It is based on data from some 70 millionWe individuals obtained data covered from by the all “Information statutory health System insurance for Health funds Care in Germany Data” located which at are the supplied German toInstitute the Federal of Medical Office Documentation of Social Security and Information to implement (DIMDI) the [morbidity-oriented21]. It is based on datarisk fromstructure some compensation70 million individuals scheme in covered the statutory by all statutory health insura healthnce insurance system. fundsThe Federal in Germany Office which of Social are Security supplied alsoto the transmits Federal Odataffice to of the Social DIMDI Security for tofurther implement use in the the morbidity-oriented Information System risk structurefor Health compensation Care Data. Eligiblescheme institutions in the statutory can healthapply insurancefor permission system. to Theanalyze Federal parts O ffiofce the of Socialdataset, Security and after also thorough transmits scrutinydata to thereceive DIMDI anonymized for further aggregate use in the data Information [22]. System for Health Care Data. Eligible institutions can applyA formal for permissionapplication to for analyze data usage parts of and the a dataset, data analysis and after script thorough were scrutiny submitted receive on 29 anonymized February 2016.aggregate At the data time [22 of]. the application, the most recent data available with information on the district level wasA formal from application2010. After adaption for data usageand a andnarrowing a data of analysis our data script request were (e.g., submitted removal on of 29 our February initial request2016. At for the high-resolution time of the application, stratification the by most age), recent our application data available was thoroughly with information screened on by the DIMDI. district Welevel received was from the 2010.final dataset After adaption on 19 December and a narrowing 2018. of our data request (e.g., removal of our initial Int. J. Environ. Res. Public Health 2020, 17, 3892 3 of 9 request for high-resolution stratification by age), our application was thoroughly screened by DIMDI. We received the final dataset on 19 December 2018. We received strongly aggregated data of individuals with at least one prescription for metamizole, and the number of packs (of any size) prescribed. Data was also provided on age (five age brackets), sex, state (Bundesland), and on the number of persons in each stratum.
Load more

Recommended publications
  • Dieses Dokument Ist Eine Zweitveröffentlichung (Verlagsversion) / This Is a Self-Archiving Document (Published Version)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Technische Universität Dresden: Qucosa Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / This is a self-archiving document (published version): Jan Gaertner, Ulrike M. Stamer, Constanze Remi, Raymond Voltz, Claudia Bausewein, Rainer Sabatowski, Stefan Wirz, Gabriele Müller-Mundt, Steffen T. Simon, Anne Pralong, Friedemann Nauck, Markus Follmann, Lukas Radbruch, Winfried Meißner Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice Erstveröffentlichung in / First published in: Palliative Medicine. 2017, 31(1), S. 26 – 34 [Zugriff am: 19.08.2019]. SAGE journals. ISSN 1477- 030X. DOI: https://doi.org/10.1177/0269216316655746 Diese Version ist verfügbar / This version is available on: https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-353637 „Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. Nationallizenz frei zugänglich.“ This publication is openly accessible with the permission of the copyright owner. The permission is granted within a nationwide license, supported by the German Research Foundation (abbr. in German DFG). www.nationallizenzen.de/ 6557467464 PMJ0010.1177/0269216316655746Palliative10.110.1177/0269216316655746177/0269216316655746Palliative MedicineGaertner et al. research-article2016 Review Article Palliative Medicine 2017, Vol. 31(1) 26 –34 Metamizole/dipyrone for the relief © The Author(s) 2016
    [Show full text]
  • Clinical Study Protocol
    CLINICAL STUDY PROTOCOL COmparison of the effect of treatment with NSAIDs added to anti- TNF therapy versus anti-TNF therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis: a randomized controlled multicentre trial (CONSUL) Protocol number: CONSUL2016 Protocol version: 1.3 including Amendment No. 1 Date: 13.02.2017 EudraCT Number: 2016‐000615‐33 Investigational Products: Golimumab, Celecoxib Study Phase: phase IV Study Design: randomized, controlled, prospective, open-label, multicentrestudy Sponsor: Charité Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin, Germany Coordinating Investigator: Prof. Dr. med. Denis Poddubnyy Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie Campus Benjamin Franklin Charité Universitätsmedizin Berlin Hindenburgdamm 30 12203 Berlin, Germany Tel: +49 30 8445-2302 or 450-514544 Fax: +49 30 8445-4149 Email: [email protected] Study Physician: Dr. med. Burkhard Muche -same address- Tel. +49 (30) 8445-4144 Email: [email protected] 4. CONSUL_Protocol_Version_1.3_with_Amendment_1_13.02.2017_clear.docx Page 1 of 61 TABLE OF CONTENT 1 LIST OF ABBREVIATIONS ................................................................................................. 4 2 PROTOCOL SYNOPSIS ..................................................................................................... 6 3 ASSESSMENT SCHEDULE .............................................................................................. 13 4 INTRODUCTION
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Metamizole-Containing Medicinal Products
    13 December 2018 EMA/143912/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Referral under Article 31 of Directive 2001/83/EC metamizole-containing medicinal products INN: metamizole sodium Procedure number: EMEA/H/A-31/1469 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Posology and maximum daily dose ......................................................................... 4 2.2.1. Single dose and maximum daily dose – adolescents and adults ............................... 4 2.2.2. Single dose and maximum daily dose – children .................................................... 8 2.2.3. Conclusion on posology and maximum
    [Show full text]
  • Analysis of Animal Well-Being When Supplementing Drinking Water with Tramadol Or Metamizole During Chronic Pancreatitis
    animals Article Analysis of Animal Well-Being When Supplementing Drinking Water with Tramadol or Metamizole during Chronic Pancreatitis Guanglin Tang 1, Wiebke-Felicitas Nierath 1, Rupert Palme 2 , Brigitte Vollmar 1 and Dietmar Zechner 1,* 1 Rudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany; [email protected] (G.T.); [email protected] (W.-F.N.); [email protected] (B.V.) 2 Unit of Physiology, Pathophysiology and Experimental Endocrinology, Department of Biomedical Sciences, University of Veterinary Medicine, 1210 Vienna, Austria; [email protected] * Correspondence: [email protected]; Tel.: +49-381-494-2512; Fax: +49-381-494-2502 Received: 11 November 2020; Accepted: 1 December 2020; Published: 5 December 2020 Simple Summary: Pain management during in vivo experiments can considerably improve the wellbeing of animals. However, often it is not clear, which drugs are best for the animals and how to apply these drugs without causing stress. In this study, we evaluated mice when metamizole or tramadol was provided via drinking water. Neither of these two drugs reduced the amount of consumed water or body weight in healthy mice or influenced their natural behavior, such as nest building or burrowing activity. Both analgesics were then given to mice suffering from chronic pancreatitis. Mice drinking tramadol supplemented water, at some time-points, experienced less loss in body weight and consumed more water than mice drinking metamizole. However, no major differences in other methods measuring wellbeing of mice was observed. In conclusion, both analgesics can be used during chronic pancreatitis, but tramadol seems to be moderately advantageous when compared to metamizole.
    [Show full text]
  • Incidence of Mucocutaneous Reactions in Children Treated with Niflumic Acid, Other Nonsteroidal Antiinflammatory Drugs, Or Nonopioid Analgesics
    Incidence of Mucocutaneous Reactions in Children Treated With Niflumic Acid, Other Nonsteroidal Antiinflammatory Drugs, or Nonopioid Analgesics Miriam Sturkenboom, PhD*‡; Alfredo Nicolosi, PhD§࿣; Luigi Cantarutti, MD¶; Salvatore Mannino, MD#; Gino Picelli‡; Antonio Scamarcia¶; and Carlo Giaquinto, MD**, for the NSAIDs Paediatric Research Group ABSTRACT. Background and Objective. Results from Participants. Children aged 0 to 14 years and regis- a relatively small case-control study recently showed that tered with 1 of the collaborating pediatricians between niflumic acid increases the risk of serious mucocutane- January 1, 1998, and May 31, 2001. ous reactions in children. As a consequence, the Italian Main Outcome Measures. The incidence rate of se- Ministry of Health sent a “Dear Doctor” letter in June vere (hospitalized or referred) and mild mucocutaneous 2001 to warn pediatricians about the alleged adverse reactions (exanthema, disseminated or localized pruritus, effects. The objective of this study was to estimate and urticaria, angioedema, fixed eruption, dermatitis, ery- compare the incidence of mild and severe mucocutane- thema multiforme, vesicles, bullae, pustules, toxic epi- ous reactions among children using niflumic acid, other dermal necrolysis, purpura, and vasculitis) was estimated nonsteroidal antiinflammatory drugs (NSAIDs), or non- during use of niflumic acid, other NSAIDs, or nonopioid analgesics. For each episode of drug use, the following opioid analgesics. covariates were assessed: age, gender, region, year, indi-
    [Show full text]
  • Dipyrone (Metamizole) –Background
    Dipyrone /Metamizole -Update Natalie Dinavitser MSc Clinical pharmacology and toxicology unit 1 Disclosure TEVA Israel has supported the conference BUT NOT FOR THIS PRESENTATION 2 Overview • Background • Safety • Efficacy • Use during pregnancy • Use during lactation 3 Dipyrone (Metamizole) –Background • Metamizole was first marketed in Germany in 1922 • Pharmacological category - NSAID’s- weak NSAID (pyrazolone family) • Has analgesic and antipyretic properties • Effective against post –operative pain ( The Cochrane collaboration 2011) • Has an anti-spasmolytic property. • The drug is registered in Israel for adults and children from 3 month of age. 4 Mechanism of action • Inhibition of a central COX -3 and activation of the opioidermic system and cannabinoid system • More than 50% binds onto plasmatic proteins : short plasmatic half- life ( I.V. 14 minutes) • Elimination – mostly renal. 5 Countries that have Dipyrone on market Austria Latvia Pakistan Brazil Belgium Lithuania China Argentina Spain Czech republic Vietnam Uruguay Germany Bulgaria Israel Paraguay Switzerland Hungary Egypt Colombia Nederland Slovenia Indonesia Peru Italy Russian federation Venezuela Greece Mexico Portugal 6 Countries where Metamizole is not approved • Sweden: banned dyirone in 1974, reintroduced metamizole in 1995, withdrew it again in 1999 • USA- Not FDA approved- withdrew dipyrone 1977 • Canada • UK • Australia- withdrew metamizole in 1964 • Norway • Finland • New Zealand • Denmark • Singapore -withdrew metamizole 1978 7 Adverse reactions: • Agranulocytosis
    [Show full text]
  • Comparison of the Pattern, Efficacy, and Tolerability of Self-Medicated Drugs in Primary Dysmenorrhea: a Questionnaire Based Survey
    Short Communication Comparison of the pattern, efficacy, and tolerability of self- medicated drugs in primary dysmenorrhea: A questionnaire based survey Ramya Sugumar, Vasundara Krishnaiah, Gokul Shetty Channaveera1, Shilpa Mruthyunjaya2 ABSTRACT Department of Pharmacology, Objective: To compare the pattern, efficacy, and tolerability of self-medicated drugs Kempegowda Institute of Medical and to assess the adequacy of their dose in primary dysmenorrhea (PD). Sciences, Bangalore, 1Jagadguru Materials and Methods: A survey using a self-developed, validated, objective, and Jayadeva Murugarajendra Medical structured questionnaire as a tool was conducted among subjects with PD. Statistical College, Davangere, 2Physiology, analysis was carried out using Chi-square test and ANOVA with post-hoc Tuckey’s test. Mysore Medical College, Mysore, Results: Out of 641 respondents, 42% were self-medicated. The pattern of drugs used Karnataka, India was: Dicyclomine, an unknown drug, mefenamic acid, mefenamic acid + dicyclomine, and metamizole by 35%, 29%, 26%, 9%, and 1% of respondents, respectively. Mefenamic Received: 24-04-2011 acid + dicyclomine, the combination was the most efficacious in comparison to other Revised: 05-08-2012 Accepted: 30-12-2012 drugs in moderate to severe dysmenorrhea. There was better tolerability with mefenamic acid + dicyclomine group compared to other drugs. Sub-therapeutic doses were used Correspondence to: by 86% of self-medicating respondents. Dr. Ramya Sugumar, Conclusions: The prevailing self-medication practices were
    [Show full text]
  • Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts Víctor J
    Int. J. Med. Sci. 2019, Vol. 16 1466 Ivyspring International Publisher International Journal of Medical Sciences 2019; 16(11): 1466-1472. doi: 10.7150/ijms.37857 Research Paper Effects of Therapeutic Doses of Celecoxib on Several Physiological Parameters of Cultured Human Osteoblasts Víctor J. Costela-Ruiz1,2, Lucia Melguizo-Rodríguez1,2, Rebeca Illescas-Montes1,2, Javier Ramos-Torrecillas1,2, Francisco J. Manzano-Moreno2,3, Concepción Ruiz1,2,4, Elvira De Luna- Bertos1,2 1. Biomedical Group (BIO277). Department of Nursing, Faculty of Health Sciences. University of Granada, Avda. Ilustración 60, 18016. Granada, Spain. 2. Instituto Investigación Biosanitaria, ibs.Granada, C/ Doctor Azpitarte 4, 4ª planta, 18012. Granada, Spain. 3. Biomedical Group (BIO277). Department of Stomatology, School of Dentistry, University of Granada, Colegio Máximo, Campus Universitario de Cartuja 18071. Granada, Spain. 4. Institute of Neuroscience, University of Granada, Centro de Investigación Biomédica (CIBM). Parque de Tecnológico de la Salud (PTS) Avda. del Conocimiento S/N, 18016. Armilla, Granada, Spain. Corresponding author: Concepción Ruiz. Faculty of Health Sciences. University of Granada. Avda. De la Ilustración 60, 18016. Granada, Spain. e-mail: [email protected] © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.06.24; Accepted: 2019.08.13; Published: 2019.09.20 Abstract Non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase-2 (COX-2)-selective NSAIDs, are associated with adverse effects on bone tissue. These drugs are frequently the treatment of choice but are the least studied with respect to their repercussion on bone.
    [Show full text]
  • Package Leaflet: Information for the User
    PACKAGE LEAFLET 1 Package Leaflet: Information for the user <Invented Name> 500 mg tablets metamizole sodium Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What <Invented Name> is and what it is used for 2. What you need to know before you take <Invented Name> 3. How to take <Invented Name> 4. Possible side effects 5. How to store <Invented Name> 6. Contents of the pack and other information 1. What <Invented Name> is and what it is used for <Invented Name> belongs to the pyrazolone group of medicines and has pain-killing and fever reducing properties. <Invented Name> 500 mg tablets are indicated in adults and children aged 10 years and older and may be applied for the treatment of - acute, severe pain following injuries or surgery, - griping abdominal pain (colic), - cancer-related pain (tumour pain), - other acute or chronic severe pain, where other therapeutic measures are not indicated, - high fever that does not respond to other measures. 2. What you need to know before you take <Invented Named> Do not use <Invented Name> - if you are allergic to metamizole sodium or other pyrazolones (e.g.
    [Show full text]
  • Dissolution Profiles of Generic and Other Drug Forms of Sodium Metamizole (Dipyrone) Sold in Brazil
    Revista de Ciências Farmacêuticas Básica e Aplicada Rev Ciênc Farm Básica Apl., 2012;33(3):347-353 Journal of Basic and Applied Pharmaceutical Sciences ISSN 1808-4532 Comparative study of the pharmacopeial quality and dissolution profiles of generic and other drug forms of sodium metamizole (dipyrone) sold in Brazil Morenna Alana Giordani1; Eduardo Borges de Melo1* 1Quality Control of Drugs Undergraduate Laboratory (Cofiqui), Dept of Pharmacy, Western Paraná State University (Unioeste), Cascavel, PR, Brazil. ABSTRACT poppy) and its opiate substitutes was already recommended to treat pain as far back as the “Great Herbarium” of the In Brazil, in order for a pharmaceutical company to Chinese Emperor Chen Nung, more than 4700 years ago. register a drug form as generic or ‘similar’ with the In the nineteenth century, several substances with analgesic Brazilian food and drug agency (Anvisa), it must be properties were introduced into therapy, among which was proved bioequivalent to its innovatory branded form the family of pyrazolones, such as antipyrine, synthesized (reference drug). This requires comparative trials, in 1884 in Germany, and metamizole (Figure 1), discovered carried out in conformity with official compendia years later (Anvisa, 2001). (Brazilian Pharmacopeia or another officially recognized code). Additionally, according to the Anvisa resolution RDC 31/2010, the dissolution profile of the drug must be tested and compared with that of the branded reference, as a benchmark of quality. The aim of this study was to assess the quality of 500 mg sodium metamizole (dipyrone) tablets produced by seven different laboratories in Brazil: three generic drugs (G1, G2, G3), three (branded) similar drugs (S1, S2, S3) and their reference branded product (Novalgina®, Sanofi-Aventis, drug R).
    [Show full text]
  • Plants As Sources of Anti-Inflammatory Agents
    molecules Review Plants as Sources of Anti-Inflammatory Agents Clara dos Reis Nunes 1 , Mariana Barreto Arantes 1, Silvia Menezes de Faria Pereira 1, Larissa Leandro da Cruz 1, Michel de Souza Passos 2, Luana Pereira de Moraes 1, Ivo José Curcino Vieira 2 and Daniela Barros de Oliveira 1,* 1 Laboratório de Tecnologia de Alimentos, Centro de Ciências e Tecnologias Agropecuárias, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (C.d.R.N.); [email protected] (M.B.A.); [email protected] (S.M.d.F.P.); [email protected] (L.L.d.C.); [email protected] (L.P.d.M.) 2 Laboratório de Ciências Químicas, Centro de Ciências e Tecnologia, UniversidadeEstadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ 28013-602, Brazil; [email protected] (M.d.S.P.); [email protected] (I.J.C.V.) * Correspondence: [email protected]; Tel.: +55-22-988395160 Academic Editors: Thea Magrone, Rodrigo Valenzuela and Karel Šmejkal Received: 29 June 2020; Accepted: 5 August 2020; Published: 15 August 2020 Abstract: Plants represent the main source of molecules for the development of new drugs, which intensifies the interest of transnational industries in searching for substances obtained from plant sources, especially since the vast majority of species have not yet been studied chemically or biologically, particularly concerning anti-inflammatory action. Anti-inflammatory drugs can interfere in the pathophysiological process of inflammation, to minimize tissue damage and provide greater comfort to the patient. Therefore, it is important to note that due to the existence of a large number of species available for research, the successful development of new naturally occurring anti-inflammatory drugs depends mainly on a multidisciplinary effort to find new molecules.
    [Show full text]